Sionna Therapeutics (NASDAQ:SION) Cut to “Market Perform” at Citizens Jmp

Citizens Jmp downgraded shares of Sionna Therapeutics (NASDAQ:SION) from an outperform rating to a market perform rating in a research report released on Monday, Marketbeat.com reports.

Several other research firms have also recently weighed in on SION. Stifel Nicolaus reaffirmed a “hold” rating and set a $7.00 price objective on shares of Sionna Therapeutics in a research report on Monday. JonesTrading lifted their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. BTIG Research restated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research note on Wednesday, May 13th. Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Finally, Guggenheim raised their price target on shares of Sionna Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Sionna Therapeutics presently has a consensus rating of “Hold” and an average price target of $42.22.

Sionna Therapeutics Stock Up 22.5%

Shares of NASDAQ:SION opened at $6.25 on Monday. The firm has a market cap of $282.56 million, a price-to-earnings ratio of -2.87 and a beta of 1.33. Sionna Therapeutics has a 12 month low of $4.01 and a 12 month high of $54.97. The company’s fifty day simple moving average is $40.38 and its 200 day simple moving average is $39.67.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). Research analysts expect that Sionna Therapeutics will post -2.65 earnings per share for the current fiscal year.

Insider Activity at Sionna Therapeutics

In related news, Director Orbimed Advisors Llc sold 85,918 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 403,726 shares of company stock valued at $18,259,354. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics in the 3rd quarter valued at about $30,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics during the second quarter worth about $31,000. State of Wyoming bought a new position in Sionna Therapeutics during the second quarter worth about $35,000. GF Fund Management CO. LTD. acquired a new position in Sionna Therapeutics during the fourth quarter worth approximately $36,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Sionna Therapeutics during the second quarter worth approximately $44,000.

Key Headlines Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: The stock’s rebound may reflect bargain hunting and short-term volatility following the steep selloff, although no new positive clinical data were reported.
• Neutral Sentiment: Analyst opinion has broadly converged around a more cautious stance. Royal Bank of Canada upgraded SION to “Sector Perform,” while Stifel Nicolaus assigned a “Hold” rating. Royal Bank of Canada upgrade
• Negative Sentiment: Sionna reported that its Phase 2a PreciSION CF trial of lead candidate SION-719 failed to achieve its key endpoint for sweat-chloride reduction. The drug will not advance as an add-on therapy, severely damaging the company’s near-term cystic-fibrosis development prospects. Sionna halts lead cystic fibrosis drug
• Negative Sentiment: The clinical failure erased roughly 90% of SION’s market value and removed a potential competitive threat to Vertex Pharmaceuticals, whose shares benefited from the news. Vertex rises as Sionna trial fails
• Negative Sentiment: Several firms reduced their ratings, including Lifesci Capital and JonesTrading to “Hold,” Wedbush to “Neutral,” Raymond James to “Market Perform,” and BTIG and Guggenheim to lower ratings. These actions signal reduced confidence after the trial result. Wedbush downgrade
• Negative Sentiment: Levi & Korsinsky announced a pending investor investigation into potential securities-law violations related to disclosures that allegedly indicated SION-719 was on track before the failed trial outcome. The investigation adds legal and reputational risk. Sionna investor investigation notice

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.